David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, ...

Patients who have had affected lymph nodes surgically removed often must undergo additional therapy to eliminate any remnant of cancer, according to David Polsky, MD, PhD, a professor in the Ronald O.

for an early indication that the melanoma is recurring," study senior author Dr. David Polsky, a dermatologic oncologist at the New York University Grossman School of Medicine, told Live Science ...

reported David Polsky, MD, PhD, of the NYU Grossman School of Medicine in New York City, and colleagues. The study "also indicated that prognosis based on pretreatment samples could be refined by ...

according to Dr. David Polsky, the Alfred W. Kopf Professor of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology at NYU, as well as an advisory board member for Novartis.

A new study finds that fragments of tumor DNA in a patient's bloodstream could show that they are at high risk of a melanoma recurrence.